NYLIM
ZNTL icon

New York Life Investment Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

New York Life Investment Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,307
Closed -$399K – 1346
2024
Q1 		$399K Buy
+25,307
New +$348K ﹤0.01% 811

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

New York Life Investment Management's ZNTL Position: Q2 2024 in Review

New York Life Investment Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2024, closing a stake of 25,307 shares — an estimated $399K sold.

New York Life Investment Management first reported a position in ZNTL in Q1 2024 and held it in 1 quarter. The position peaked at $399K in Q1 2024. 145 funds tracked by Wall St. Rank hold ZNTL as of Q2 2024.

  • New York Life Investment Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 25,307 Zentalis Pharmaceuticals shares in Q2 2024, an estimated $399K.
  • New York Life Investment Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • New York Life Investment Management's Zentalis Pharmaceuticals position peaked at $399K in Q1 2024.
  • 145 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.